Ramón
García Sanz
Profesor Titular de Universidad
Ottawa Hospital
Ottawa, CanadáPublicaciones en colaboración con investigadores/as de Ottawa Hospital (3)
2023
-
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia
Future Oncology, Vol. 19, Núm. 5, pp. 345-353
2022
-
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 1, pp. 52-62
2018
-
Phase 3 trial of Ibrutinib plus rituximab in Waldenstrom's macroglobulinemia
New England Journal of Medicine, Vol. 378, Núm. 25, pp. 2399-2410